Summary
B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were constructed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence (P<0.05). The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol, 2002,71(6):907–920
Pardoll D, Allison J. Cancer immunotherapy: Breaking the barriers to harvest the crop. Nat Med, 2004,10(9):887–892
Lyman MA, Aung S, Biggs JA, et al. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol, 2004,172(11):6558–6567
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8(8):793–800
Junko H, Mingcong W, Megumi M, et al. B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts. J Immunol, 2006,177(21): 5928–5935
Fumihiko T, Kae T, Noriko O, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol, 2006,42(3): 268–274
Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-Related Molecule B7-H1 by Glioma Cells: A Potential Mechanism of Immune Paralysis. Cancer Res, 2003,63(21):7462–7467
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol, 2007,19(7):813–824
He L, Zhang G, He Y, et al. Blockade of B7-H1 with sPD1 improves immunity against murine hepatocarcinoma. Anticancer Res, 2005,25(5):3309–3313
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999, 5(12):1365–1369
Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death 1 ligands on dendritic cells enhanced T cell activation and cytokine production. J Immunol, 2003,170(3):1257–1266
Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 2004,10(15):5094–5100
Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 2006,8(3):190–198
Strome SE, Dong H, Tamura H, et a1. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res, 2003,63(19): 6501–6505
Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res, 2006,66(7):3381–3385
Das S, Suarez G, Beswick EJ, et al. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol, 2006, 176(5):3000–3009
Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1(B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer, 2006,119(2):317–327.
Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res, 2005, 65(3):1089–1096.
Yoshsiko I, Masayoshi I, Yoshimasa T, et a1. Involvement of PD-LI on tumor cells in the escape from host immune system and tumor immunotherapy by PD-LI blockade. Proc Natl Acad Sci USA, 2003,99(19): 12293–12297
Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med, 2003,9(5):562–567
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by a grant from Hubei Provincial Science and Technology Key Program Foundation of China (No. 2007AA402C60).
Rights and permissions
About this article
Cite this article
Wang, Y., Zhuang, Q., Zhou, S. et al. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 29, 77–79 (2009). https://doi.org/10.1007/s11596-009-0116-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-009-0116-2